Loading
A phase 1/2 trial of SHR-A2102, Adebrelimab, Cisplatin in non-small-cell lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06512051 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 248 participants planned, started 2024-07-30 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection, Carboplatin injection, Bevacizumab Injection. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Bevacizumab, Cisplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/